Somnomed Limited · ASX:SOM
Somnomed — Canaccord Drug & Devices Conference 2025
9 slides from Somnomed's conference presentation, Oct 21, 2025
Slide 1: Sleep Medicine – Is the revolution real?
For personal use only Sleep Medicine – Is the revolution real? Canaccord Drug & Devices Conference in Noosa October 2025
Slide 2: Disclaimer
Disclaimer This document has been prepared as a summary only and does not contain all information about SomnoMed Limited’s (the Company’s) assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s securities. This document
Slide 3: SomnoMed is the global leader in Oral Appliance Therapy (OAT)
SomnoMed is the global leader in Oral Appliance Therapy (OAT) Overview FY25 highlights For personal use only 20+ Countries with operational +22% Revenue growth in FY25 to $111.5m presence 20+ Years of product development $9.2m EBITDA1 vs $0.6m in FY24 7,000+ Dental sleep relationships globally Posit
Slide 4: Structural tailwinds are driving growth in OSA treatment
Structural tailwinds are driving growth in OSA treatment Growth Forecast Structural Growth Drivers For personal use only Estimated Global OSA Treatment Market CAGR (%) Increased awareness 17%2 Data and health economics 10%1 7% Medical guidelines and reimbursement FY25 FY26 FY27 FY28 FY29 FY30 FY31 F
Slide 5: OAT is an effective solution to treat OSA
OAT is an effective solution to treat OSA For personal use only 100% 50% of patients stop using Poor CPAP compliance is widely regarded CPAP after 6 as a limiting factor in treating OSA1,2,3,4,5 months 50% 41% OAT is an effective and reimbursed alternative to CPAP6 Baseline 1 year 6 years 1. Rotenbe
Slide 6: The health economics of OAT will support the disruption of the OSA treatment market
The health economics of OAT will support the disruption of the OSA treatment market For personal use only OAT Hypoglossal Nerve CPAP Stimulation and other Surgical Procedures 5yr Cost Low – Med Med – High Very High Invasiveness Low Moderate High Compliance High Low - Moderate High 66
Slide 7: Rest Assure sets a new standard with continuous monitoring in OAT
Rest Assure® sets a new standard with continuous monitoring in OAT For personal use only ü Rest Assure® is a SomnoDent Avant® with embedded sensors enabling nighttime monitoring ü Provides CPAP equivalent data for compliance and efficacy of OAT ü Data to support modifying medical guidelines and reim
Slide 8: SomnoMed is well positioned for growth in the expanding OSA market
SomnoMed is well positioned for growth in the expanding OSA market. For personal use only Significant total addressable market with 900+ million individuals suffering from OSA globally. Increasing consumer awareness, growth in GLP-1 drugs, and demand for CPAP alternatives is growing the OAT market.
Slide 9: Thank you
For personal use only Thank you